Näytetään tulokset 1 - 10 / 24
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi

Health-related quality-of-life results from the phase 3 OPTIMISMM study:pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1080/10428194.2020.1747066
Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Ab...
Leukemia & lymphoma2020

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma:a practical review

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/bjh.18295
McCaughan, Georgia J.; Gandolfi, Sara; Moore, John J.; Richardson, Paul G.
British journal of haematology2022

Bortezomib treatment causes long-term testicular dysfunction in young male mice

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/1476-4598-13-155
Hou, Mi; Eriksson, Emma; Svechnikov, Konstantin; Jahnukainen, Kirsi; Soder, Olle; Meinhardt, Andreas...
Molecular cancer2014

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

Vertaisarvioitu
Salmenniemi U; Remes K
Hematology reports2012

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

Avoin saatavuus
Urpu Salmenniemi, Kari Remes
Hematology Reports2012

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy

Sinisalo M; Silvennoinen R; Wirta O
American Journal of Hematology2012

Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers13102341
Örd, Tiit; Örd, Daima; Kaikkonen, Minna U.; Örd, Tõnis
Cancers2021

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma – a Nordic Myeloma Study Group randomized phase 3 trial

Vertaisarvioitu
DOI
10.1182/blood-2012-11-464503
Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, ...
Blood2013

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

DOI
10.1111/bjh.12139
Silvennoinen, Raija; Kairisto, Veli; Pelliniemi, Tarja-Terttu; Putkonen, Mervi; Anttila, Pekka; Sail...
British journal of haematology2013

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Vertaisarvioitu
DOI
10.1111/bjh.12139
Silvennoinen, Raija; Kairisto, Veli; Pelliniemi, Tarja-Terttu; Putkonen, Mervi; Anttila, Pekka; Säil...
British journal of haematology2013

Health-related quality-of-life results from the phase 3 OPTIMISMM study:pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1080/10428194.2020.1747066
2020

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma:a practical review

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/bjh.18295
2022

Bortezomib treatment causes long-term testicular dysfunction in young male mice

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/1476-4598-13-155
2014

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

Vertaisarvioitu
2012

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

Avoin saatavuus
2012

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy

2012

Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers13102341
2021

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma – a Nordic Myeloma Study Group randomized phase 3 trial

Vertaisarvioitu
DOI
10.1182/blood-2012-11-464503
2013

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

DOI
10.1111/bjh.12139
2013

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Vertaisarvioitu
DOI
10.1111/bjh.12139
2013